Nervonic Acid
1. Identity: Chemical and Botanical Profile
1.1 Chemical Names and Classification
Nervonic acid (C24:1 Δ15, cis-15-tetracosenoic acid) is a very long-chain fatty acid whose name originated from the original discovery in mammalian nerve tissues. It belongs to the group of unsaturated fatty acids — bearing one cis double bond — classified in the omega-9 (ω-9) or n-9 sub-family, represented in shorthand as 24:1n-9, and is a member of the very long chain fatty acids (VLCFA) subgroup, comprising fatty acids of 20 carbons or more.
Its key physicochemical identifiers are: molecular weight 366.62 g/mol; molecular formula C₂₄H₄₆O₂; IUPAC name (Z)-tetracos-15-enoic acid; PubChem CID 5281120. The compound is also known by the historic synonym selacholeic acid, derived from its early isolation from shark tissues. In its purified form, nervonic acid is a clear to yellowish crystalline powder insoluble in water, with a melting point of 42.5–43 °C.
1.2 Discovery and Historical Nomenclature
Nervonic acid was first discovered by Tsujimoto M. in 1927 in the fats of Elasmobranch fishes — a subclass of cartilaginous fish including sharks (from which it derived its first name, selacholeic acid) and rays. Its structure was established in the same year by Klenk E., who isolated it from cerebrosides of brain tissue.
1.3 Natural Sources
In nature, nervonic acid has been synthesized by a handful of plants, fungi, and microalgae. Plant-derived sources are the most studied. Traditional plant-derived nervonic acid is obtained from seeds of Acer truncatum Bunge, Malania oleifera Chun, and Xanthoceras sorbifolium Bunge via pressing and refining processes.
Nervonic acid is found in the seed oils of some wild plants, including Lunaria annua (honesty), Acer truncatum (purpleblow maple), Tropaeolum speciosum (flame flower), Borago officinalis (borage), and Cannabis sativa (hemp). A broader survey of natural sources includes the following:
- Natural sources include the seed oils of Cardamine gracea, Heliphila longifola, Thlaspi perfoliatum, Tropaeolum speciosum, Lunaria biennis, Lunaria annua, and Malania oleifera; the moulds Neocallismastix frontalis, Erysiphe graminis, and Sphaerotheca humuli; the bacterium Pseudomonas atlantica; the yeast Saccharomyces cerevisiae; and the marine diatom Nitzschia cylindrus.
Among plant sources, Malania oleifera stands out for exceptionally high concentration. The seed oil of Malania oleifera contains nervonic acid at up to 40.92–50% of total lipid, is native to southern China in the western provinces of Guangxi and southeastern Yunnan, but is a threatened species on the list of key wild plants for state protection. The seed oils of Lunaria species such as Lunaria biennis are of particular value since they contain over 20% nervonic acid in the triglyceride lipid. Acer truncatum seed oil is composed mainly of triacylglycerols with approximately 90% unsaturated fatty acids, of which nervonic acid constitutes approximately 5.5%.
As a naturally occurring fatty acid in human milk, nervonic acid helps with myelination in the early stages of life. The nervonic acid concentration in human milk is highest in colostrum (0.76 ± 0.23 mg/g fat) and significantly decreases over the course of the first month of lactation.
1.4 Common Forms and Preparations
Nervonic acid is primarily sourced through plant extraction, chemical synthesis, and microbial biosynthesis. It can be separated and purified by urea adduction fractionation, molecular distillation, and crystallization. Commercial preparations available as dietary supplements typically consist of highly purified nervonic acid extracted from Acer truncatum seed oil, offered at stated purities of 90%, 95%, 97%, and 98%. Recent advances in biotechnology have made it feasible to produce high nervonic acid-containing oil through fermentation, presenting a significant opportunity to address the nutritional gap in infant formula. The biosynthesis of nervonic acid is generally considered to start from oleic acid through fatty acid elongation, in which malonyl-CoA and long-chain acyl-CoA are first condensed by a rate-limiting enzyme 3-ketoacyl-CoA synthase (KCS); heterologous expression of the kcs gene from high nervonic acid-producing species in plants and yeast has led to synthesis of nervonic acid.
2. Traditional and Historical Use
2.1 Chinese Ethnobotanical Traditions
Acer truncatum Bunge is a multifunctional plant in northern China, and has traditionally been used to prevent cardiovascular and cerebrovascular diseases and treat skin trauma by different linguistic groups including Mongolian, Tibetan, and Korean. It has been used as a traditional herbal medicine in northern China for centuries.
Acer truncatum is referred to in China as "yuan bao feng" because of its gold ingot-shaped fruits, and has historically been used for landscaping. Its leaves are used to produce health-promoting tea and folk medicines for treating cerebrovascular diseases and angina pectoris, owing to their substantial abundance in tannins, flavonoids, and chlorogenic acid. Its leaves have been used as medicinal herbs and as the raw material for maple tea in China, and there is a tradition of directly eating its fried seeds.
It is important to note that the traditional use of Acer truncatum in Chinese and related traditions encompassed the whole plant — its leaves, bark, and seeds — rather than an isolated nervonic acid fraction. Research has subsequently verified that A. truncatum contains nervonic acid as an important component in delaying brain aging, although no traditional monograph specifically identified nervonic acid as the isolated active constituent. The isolation and characterization of nervonic acid as a discrete chemical entity is a product of 20th-century science; its targeted supplementation as a purified compound is a contemporary practice.
2.2 Role in Infant Feeding Traditions
Nervonic acid is a natural component of maternal milk that promotes infant growth during nervous system development. The presence of nervonic acid in breast milk has been recognized across cultures, though formal characterization of its nutritional significance emerged from modern biochemical research rather than from traditional medical systems.
3. Key Constituents, Biochemistry, and Mechanisms of Action
3.1 Role in Sphingolipid and Myelin Metabolism
Nervonic acid combines with sphingosines via amide bond to form nervonyl sphingolipids, which are an important component of the white matter of brains and myelinated nerve fibers. Myelin is a lipid sheath wrapped around nerve fibers that serves two main functions: it protects the nerve fibers and accelerates the transmission of nerve impulses.
In the human brain, nervonic acid and lignoceric acid together make up 60% of the fatty acids of sphingomyelin of white matter (lignoceric acid is a saturated fatty acid also consisting of 24 carbon atoms). As the major monounsaturated fatty acid in sphingomyelin that contributes to the formation of the myelin sheath, nervonic acid is crucial for the development and maintenance of the brain and nervous system.
Studies indicate that nervonic acid supplementation can enhance myelin synthesis in oligodendrocytes, promoting nerve maturation. Once produced, nervonic acid is incorporated into sphingomyelin and gangliosides — major lipid constituents of the myelin sheath that insulate axons, enabling rapid and efficient nerve impulse conduction. Nervonic acid facilitates proper signal transduction and cell recognition, contributing to optimal neural connectivity and long-term neurodevelopmental outcomes.
3.2 Endogenous Biosynthesis and Dietary Dependency
Nervonic acid is produced endogenously from oleic acid, which undergoes three consecutive chain elongation steps catalyzed by elongases. Two carbon units are added in each step, with production of gadoleic acid, erucic acid, and finally nervonic acid. However, due to limited synthesis in humans, nervonic acid is primarily obtained through plant extraction, chemical synthesis, or biosynthetic methods. As a critical component of neural myelin sheaths, it maintains nerve cell structural integrity and function.
3.3 Mechanisms of Action in Disease Contexts
Several interrelated mechanisms have been characterized or proposed for nervonic acid's bioactivity:
- Reversal of saturated VLCFA accumulation (ALD context): Nervonic acid can reverse total lipid C26:0 accumulation in a concentration-dependent manner in ALD cell lines and can protect ALD fibroblasts from oxidative insults.
- Mitochondrial support: Nervonic acid was observed to concurrently increase ATP production and indirectly offer cytoprotection in ALD cells.
- Neurogenesis and angiogenesis (preclinical): The mechanism of nervonic acid promoting nerve regeneration lies in the upregulation of secretion of NGF, NF-200, and S100 protein, and nervonic acid treatment was also able to up-regulate VEGF and CD31 to directly promote angiogenesis during wound healing.
- Oligodendrocyte maturation (in vitro): During acute inflammation, nervonic acid synthesis is silenced, shifting the lipid metabolism pathway of common substrates into proinflammatory arachidonic acid production. In experiments on human models of maturating oligodendrocyte precursor cells (hOPCs) in vitro, a fish oil mixture (FOM) affected their function, resulting in improved synthesis of myelin basic protein, myelin oligodendrocyte glycoprotein, and proteolipid protein, as well as sphingomyelin.
- Gut–brain axis modulation: Nervonic acid mediates bidirectional gut–brain regulation through the "Gut Microbiota–Metabolite–Neuroinflammation" axis (MGBA).
- Metabolic syndrome and lipid balance: The level of nervonic acid directly influences the balance of metabolic syndrome (MetS) and serum plasmalogens. In individuals with MetS, levels of nervonic acid (C24:1), behenic acid (C22:0), and lignoceric acid (C24:0) are significantly reduced, accompanied by a decrease in HDL-C and an increase in TG and sdLDL-C, indicating exacerbated lipid metabolism abnormalities.
4. Scientific Evidence by Area of Use
4.1 Brain Development and Infant Nutrition
The first year of life is a critical period of rapid brain growth and neural development, during which fundamental processes such as myelination, synaptogenesis, and neurotransmitter synthesis occur at an accelerated rate, shaping cognitive and sensory functions. Nervonic acid (24:1 n-9) plays a fundamental role in brain development, particularly in the biosynthesis of sphingolipids and myelin sheaths. It is present in minute amounts in human milk, and despite its importance in neuronal function and cognitive development, there is currently no approved ingredient available for the fortification of infant nutrition products.
The nervonic acid level is considered to reflect brain maturation, and its accumulation in the brain is a sign of the onset of myelinogenesis. Newborns who cannot be breastfed fail to get sufficient levels of nervonic acid from infant formulae; long-term nervonic acid deficiency can hamper the development of the nervous system and cause visual impairment.
Formula-fed infants receive markedly lower nervonic acid levels than their breastfed counterparts. Given its role in neural membrane formation and myelination, its limited presence in infant formula raises concerns regarding potential neurodevelopmental implications. These findings highlight the need for further research into nervonic acid fortification in infant nutrition products to better align with the composition of human milk.
Evidence strength: The infant nutrition evidence base is currently observational and mechanistic. No large-scale randomized controlled trials (RCTs) specifically testing isolated nervonic acid supplementation in infants have been published as of the sources reviewed. Studies on MFGM-containing formulas (which are rich in sphingomyelin) show cognitive benefits, but these do not isolate nervonic acid as the active constituent.
4.2 Adrenoleukodystrophy (ALD) and Related Peroxisomal Disorders
Adrenoleukodystrophy (ALD) is an X-linked inherited peroxisomal disorder due to mutations in the ALD protein, characterized by accumulation of very long-chain fatty acids (VLCFA), specifically hexacosanoic acid (C26:0). This can trigger other pathological processes such as mitochondrial dysfunction, oxidative stress, and inflammation, which if it involves brain tissues can result in a lethal form called childhood cerebral ALD.
Sphingolipids from post-mortem ALD brain have decreased levels of nervonic acid (24:1n-9) and increased levels of stearic acid (18:0). In a 2022 study published in Neurotherapeutics, Terluk et al. used ALD patient-derived fibroblasts to examine nervonic acid as a potential therapy: nervonic acid was shown to reverse total lipid C26:0 accumulation in a concentration-dependent manner in ALD cell lines and protect ALD fibroblasts from oxidative insults. Nervonic acid was also observed to concurrently increase ATP production and indirectly offer cytoprotection in these cells.
A 2025 study in the British Journal of Pharmacology by Li et al. investigated nervonic acid in adrenomyeloneuropathy (AMN) fibroblasts (a milder form of ALD): Adrenomyeloneuropathy (AMN) is a progressive inherited metabolic disease characterized by accumulation of saturated very long-chain fatty acids in plasma and tissues, leading to increasing oxidative stress, mitochondrial dysfunction, neuroinflammation, cognitive dysfunction and disability. Preclinical and clinical investigations have indicated that nervonic acid holds the potential to alleviate motor, cognitive and neurological impairments. Preliminary evidence suggests that nervonic acid can also modulate cellular antioxidant defence systems and inflammation in neurodegenerative conditions, rendering it a promising therapeutic candidate.
A 2026 animal intervention study published in Neurotherapeutics by Li et al. provided further evidence: a 4-week dietary intervention study using a mouse model of ALD showed that nervonic acid treatment significantly decreased plasma C26:0-lysophosphatidylcholine, a diagnostic and disease-severity biomarker of ALD, by about 60% as early as one week after intervention; after 4 weeks, nervonic acid markedly reduced free C26:0 and total saturated VLCFA levels in plasma and tissues, and an approximately 56% reduction in brain C26:0-lysophosphatidylcholine levels was observed in nervonic acid-fed mice — an effect not previously reported with other drug interventions. Comparative microbiome analysis showed for the first time distinct baseline differences between ALD and wild-type mice, with dietary fatty acid supplementation preventing further dysbiosis; no adverse effects on body weight or food intake were observed throughout the study.
Further investigation of nervonic acid as a potential and safe therapy for ALD is considered warranted. In vivo studies with nervonic acid will need to assess its biochemical and physiological effects, and the safety, toxicity, and efficacy of nervonic acid will also need to be better evaluated in relevant animal models to understand short-term and long-term exposure effects on blood and tissues including the liver, heart, adrenals, spinal cord, and brain.
Evidence strength: Preclinical (cell lines and mouse models). No human clinical trials of nervonic acid for ALD have been published. The existing preclinical evidence is mechanistically coherent and shows biochemical effects, but human efficacy data are absent.
4.3 Multiple Sclerosis and Demyelinating Diseases
The dysfunction of oligodendrocytes (OLs) is regarded as one of the major causes of inefficient remyelination in multiple sclerosis, resulting gradually in disease progression. Oligodendrocytes are derived from oligodendrocyte progenitor cells (OPCs), which populate the adult central nervous system, but their physiological capability for myelin synthesis is limited. The low intake of essential lipids for sphingomyelin synthesis in the human diet may account for increased demyelination and reduced efficiency of the remyelination process.
In a study on lipid profiling in an experimental autoimmune encephalomyelitis brain, it was revealed that during acute inflammation, nervonic acid synthesis is silenced, as an effect of shifting the lipid metabolism pathway of common substrates into proinflammatory arachidonic acid production. In experiments on the human model of maturating oligodendrocyte precursor cells (hOPCs) in vitro, a fish oil mixture (FOM) affected hOPC function, resulting in improved synthesis of myelin basic protein, myelin oligodendrocyte glycoprotein, and proteolipid protein, as well as sphingomyelin; additionally, FOM reduced proinflammatory cytokines and chemokines and enhanced FGF2 and VEGF synthesis. Based on these observations, it was proposed that the intake of FOM rich in nervonic acid ester may improve oligodendrocyte function, affecting OPC maturation and limiting inflammation.
A lack of nervonic acid is associated with demyelinating diseases such as multiple sclerosis and adrenoleukodystrophy.
Evidence strength: Preliminary. Current evidence is limited to in vitro models (human oligodendrocyte precursor cells) and animal models. No dedicated human clinical trials testing nervonic acid alone for multiple sclerosis have been published.
4.4 Psychiatric Disorders: Schizophrenia and Psychosis Risk
Nervonic acid plays a crucial role in myelination and motor function, and it also regulates cognitive and metabolic functions, suggesting that impaired nervonic acid metabolism may contribute to the pathophysiology of schizophrenia.
In a 2012 paper published in Molecular Psychiatry by Amminger et al., decreased nervonic acid levels in erythrocyte membranes were examined as a predictor of psychosis in help-seeking ultra-high-risk individuals. Although several studies have measured erythrocyte membrane nervonic acid in first-episode psychosis (FEP), findings are conflicting, and the fate of nervonic acid in patients with chronic schizophrenia or under long-term antipsychotic treatment schedules remains unknown. In one study, twenty-one drug-naive patients with FEP, twenty patients with chronic schizophrenia treated with atypical antipsychotics, and fourteen healthy male subjects were analyzed. The conclusion reached was that erythrocyte membrane nervonic acid could be used as a biomarker for predicting treatment resistance and for prognosis in patients with schizophrenia and other psychiatric diseases.
A pilot study also assessed plasma nervonic acid as a potential biomarker for major depressive disorder.
Evidence strength: Biomarker-level evidence only. Reduced erythrocyte nervonic acid has been reported in individuals at ultra-high risk of psychosis, but the existing evidence comprises small observational studies with conflicting findings. No RCTs of nervonic acid supplementation for schizophrenia or psychosis prevention have been identified in the sources reviewed.
4.5 Cognitive Function and Neurodegeneration (Alzheimer's Disease, Parkinson's Disease)
Nervonic acid's bioactive properties encompass mitigating oxidative stress and improving cognitive function. Increasing research has shown that nervonic acid is associated with many neurological diseases such as demyelinating diseases, multiple sclerosis, Alzheimer's disease, and Parkinson's disease.
A positive correlation between MMSE score and nervonic acid (C24:1n-9) in individuals with mild cognitive impairment (MCI) has been observed (r = 0.54, p = 0.01). The association of nervonic acid with MMSE may prove to be interesting because nervonic acid is required in the synthesis of nerve cell myelin and was recently shown to be decreased in erythrocyte membranes in individuals at high risk of psychosis.
Brain sphingomyelin levels are consistent with nervonic acid levels in red cells; it has significant biological functions such as promoting brain development, improving memory, and delaying brain aging.
Evidence strength: Predominantly associative and preclinical. The correlation between nervonic acid levels and cognitive test scores is based on small observational studies. In vitro and animal model data exist for Parkinson's and Alzheimer's disease models, but no registered human clinical trials specifically testing nervonic acid supplementation for these conditions have been identified in the sources reviewed.
4.6 Wound Healing and Peripheral Nerve Regeneration
Rapid tissue reconstruction in acute and chronic injuries is challenged by the difficulty in simultaneously promoting the regeneration of peripheral nerves and vasculature. A 2024 study in Frontiers in Pharmacology demonstrated for the first time that: nervonic acid isolated from Malania oleifera has the potential to simultaneously promote both neurogenesis and angiogenesis in vitro and in vivo. In a model of oxidative stress in neural cells induced by hydrogen peroxide, nervonic acid protected cell viability of RSC96 and PC12 cells from oxidative stress injury. In a rat wound healing model, effective blood vessel formation and wound healing were observed under nervonic acid treatment. The mechanism of nervonic acid promoting nerve regeneration lies in the upregulation of NGF, NF-200, and S100 protein secretion, while nervonic acid treatment up-regulated VEGF and CD31 to directly promote angiogenesis during wound healing.
Evidence strength: Preclinical (in vitro and rodent models only). No human clinical data for wound healing are available from the sources reviewed.
4.7 Cardiovascular Health and Metabolic Disease
Studies on nervonic acid functionality have involved treatments for demyelinating diseases and acquired immunodeficiency syndrome, as well as prediction of mortality due to cardiovascular diseases and chronic kidney disease. Nervonic acid (C24:1), as a component of membrane sphingolipids and phosphatidylethanolamines, may be a useful predictor of chronic kidney disease mortality and diabetes.
In individuals with metabolic syndrome, levels of nervonic acid (C24:1), behenic acid (C22:0), and lignoceric acid (C24:0) are significantly reduced, accompanied by a decrease in HDL-C and an increase in TG and sdLDL-C, indicating exacerbated lipid metabolism abnormalities. Nervonic acid can be used as a special and promising biomarker, showing significant potential in psychiatric disorders, cognitive impairments, and metabolic diseases. Increasing evidence suggests that changes in nervonic acid levels not only reflect the metabolic and neurological status of the body but also serve as a crucial indicator for disease diagnosis, monitoring progression, and evaluating treatment efficacy.
Evidence strength: Biomarker and epidemiological-level evidence. No interventional clinical trials using nervonic acid specifically to improve cardiovascular or metabolic outcomes have been identified in the sources reviewed.
4.8 Anti-inflammatory and Gut Microbiota Effects
Nervonic acid's bioactive properties include balancing pro-/anti-inflammatory factors to alleviate inflammation in organs such as the liver or colon, while modulating gut microbiota. Its applications encompass mitigating oxidative stress and improving cognitive function; balancing pro-/anti-inflammatory factors to alleviate inflammation in organs such as the liver or colon while modulating gut microbiota; and its level fluctuations being closely associated with psychiatric disorders and metabolic diseases, demonstrating biomarker potential for early diagnosis.
Comparative microbiome analysis in an ALD mouse model showed for the first time distinct baseline differences between ALD and wild-type mice, with dietary nervonic acid supplementation preventing further dysbiosis.
Evidence strength: Primarily preclinical (animal and cell-based). Human evidence for anti-inflammatory effects of nervonic acid per se is not established.
5. Body Systems and Health Areas Associated with Nervonic Acid
- Central nervous system: Myelin sheath formation, white matter integrity, oligodendrocyte function, sphingolipid biosynthesis.
- Peripheral nervous system: Nerve fiber repair, regeneration of myelinated peripheral nerve fibers.
- Neurodevelopment: Infant brain myelination, cognitive development, white matter maturation.
- Neurological disease: Demyelinating conditions (ALD, MS), neurodegenerative conditions (Alzheimer's, Parkinson's), psychiatric conditions (schizophrenia, major depressive disorder — as a biomarker).
- Cardiovascular/metabolic system: Associated with metabolic syndrome, HDL-C balance, plasmalogen levels, and chronic kidney disease mortality risk as a biomarker.
- Wound repair and tissue regeneration: Neural and vascular regeneration in acute and chronic wounds (preclinical only).
- Gastrointestinal/gut microbiome: Modulation of gut microbiota composition via the gut–brain axis (preclinical).
6. Dosage Forms and Doses Reported in Studies
Formal dosage-finding or dose-escalation human clinical trials for isolated nervonic acid supplementation have not been identified in the reviewed literature. The following dosage information reflects what has appeared in preclinical or nutritional contexts as reported in the sources:
- Infant formula / enteral foods: Enteral foods or infant foods have been prepared containing between 0.5–20% nervonic acid or a functional derivative thereof.
- ALD mouse model: A 4-week dietary intervention study using a mouse model of ALD was conducted to evaluate safety and therapeutic efficacy. Specific dose amounts in mg/kg are not stated in the abstract sources reviewed.
- Human milk reference values: Nervonic acid concentration in human colostrum was reported as 0.76 ± 0.23 mg/g fat.
No peer-reviewed human RCT defining an optimal therapeutic dose of isolated nervonic acid for any indication was identified in the sources reviewed. The safety, toxicity, and efficacy of nervonic acid will need to be better evaluated in relevant animal models as it allows for the understanding of short-term and long-term exposure effects on blood and tissues such as the liver, heart, adrenals, spinal cord, and brain.
7. Safety Considerations and Interactions
7.1 General Safety Profile in Preclinical Models
In the 4-week ALD mouse dietary intervention study, no adverse effects on body weight or food intake were observed throughout the study. Further investigation of nervonic acid as a potential and safe therapy for ALD is warranted, and in vivo studies will need to assess its biochemical and physiological effects.
7.2 Structural Relationship to Erucic Acid: A Noted Concern
Nervonic acid (C24:1 n-9) is the elongation product of erucic acid (C22:1 n-9). Because plant oils rich in nervonic acid — notably Lunaria species — frequently co-occur with substantial erucic acid, erucic acid content is a recognized analytical and safety concern when sourcing nervonic acid from unrefined plant oils. In transgenic Brassica napus, engineering approaches resulted in 30% nervonic acid but with 20% residual erucic acid; the erucic acid content in such cases is too high for human or animal consumption, making specifically engineered low-erucic acid, high-nervonic acid oils the most suitable candidates for pharmaceutical/nutraceutical applications. This concern does not apply to highly purified nervonic acid isolates where erucic acid has been removed, but it is relevant when nervonic acid is consumed in whole seed oil form from species such as Lunaria.
7.3 Human Synthesis Limitations and Deficiency Contexts
Nervonic acid is a critical component of neural myelin sheaths that maintains nerve cell structural integrity and function; due to limited synthesis in humans, it is primarily obtained through plant extraction, chemical synthesis, or biosynthetic methods. Long-term nervonic acid deficiency has been linked to hampering of nervous system development and visual impairment in infants.
7.4 Availability for Infant Formula Fortification
Nervonic acid is present in minute amounts in human milk, and despite its importance in neuronal function and cognitive development, there is currently no ingredient available for the fortification of infant nutrition products. This represents both a regulatory gap and a safety consideration for formula-fed infants, particularly those born prematurely. Premature birth, defined as delivery before 37 weeks of gestation, is associated with an increased risk of neurodevelopmental disorders, primarily due to disrupted brain maturation during the third trimester, a critical period for myelination and white matter development.
7.5 Status as a Biomarker vs. Therapeutic Agent
Nervonic acid can be used as a promising biomarker with significant potential in various fields such as psychiatric disorders, cognitive impairments, and metabolic diseases. Increasing evidence suggests that changes in nervonic acid levels not only reflect the metabolic and neurological status of the body but also serve as a crucial indicator for disease diagnosis, monitoring progression, and evaluating treatment efficacy. The distinction between nervonic acid as a diagnostic biomarker and as a therapeutic supplement remains important: the majority of association studies demonstrate correlations between nervonic acid status and disease outcomes, but do not establish that supplementation itself corrects those outcomes in humans.
7.6 Gaps in Safety Data
Comprehensive human safety data for supplemental nervonic acid across a range of doses, durations, and populations are not available from the sources reviewed. Nervonic acid has gained increasing attention because of its potential neuroprotective and anti-inflammatory properties; nonetheless, the beneficial effects of nervonic acid are yet to be fully investigated. Formal toxicological studies in humans, including assessments for hepatotoxicity, cardiac effects, or drug interactions, have not been identified in the peer-reviewed literature reviewed here.
References
Go back